Advertisement Pharmaceutical Business review - Page 67 of 5257 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 16, 2026

Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal

Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and potential commercialisation of its botensilimab and balstilimab (BOT/BAL) immunotherapy combination programme.

After closing, Emeryville and Berkeley manufacturing facilities will transfer to Zydus under the newly formed Zylidac Bio subsidiary. Credit: Piotr Swat / Shutterstock.com.